Alex Aliper

[Alex Aliper @AlexAliper]

How AI turbocharged the development of a new drug and what it might mean for health care https://t.co/8y54nVjfzs

[Alex Zhavoronkov, PhD (aka Aleksandrs Zavoronkovs) @biogerontology]

Big paper alert: TNIK inhibitor designed using generative AI targets fibrosis in preclinical and clinical trials
https://t.co/uzHlXh4pBq

[Nature Biotechnology @NatureBiotech]

A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models https://t.co/rXF9xINiFs

[Alex Aliper @AlexAliper]

Great news on Friday: the paper about our most advanced therapeutic program against Idiopathic Pulmonary Fibrosis just got published in Nature Biotechnology: https://t.co/DmvRjTmPgb

Congratulations to the Team! 👏

@InSilicoMeds @biogerontology

[Alex Aliper @AlexAliper]

No humans allowed: Alex Zhavoronkov adds robotic lab to his AI drug discovery play as Insilico unveils $60M raise - https://t.co/Ob5zCHMAA3

[Daniel Kraft, MD @daniel_kraft]

New research published in Aging describes how ⁦@InSilicoMeds⁩ PandaOmics software was able to predict molecular targets for new drugs to Rx both aging & age-associated diseases like Alzheimer’s, Parkinson’s, cirrhosis, RA & more…

#AI #pharma https://t.co/PD0qLJQ4MX

[Alex Zhavoronkov, PhD (aka Aleksandrs Zavoronkovs) @biogerontology]

We just did something fun. Discovered a target without a structure, used AlphaFold-predicted structure for SBDD, got a weak hit in about 30 days. @A_Aspuru_Guzik @MLevitt_NP2013 #alphafold
Check out and critique the pre-print as we wait for better hits https://t.co/bCEmGlksCg

[Insilico Medicine @InSilicoMeds]

Today @InSilicoMeds is thrilled to announce our most important news to date - our antifibrotic program has now progressed to the First-in-Human stage! https://t.co/bSwrhDCWEE

[Alex Aliper @AlexAliper]

https://t.co/JffEzPLYJ1

[Alex Aliper @AlexAliper]

Insilico Medicine Announces an AI-driven PROTAC R&D Collaboration with Arvinas https://t.co/QsrHyc6j7D

[Insilico Medicine @InSilicoMeds]

Today we are ready to reveal our new partner - Usynova Pharmaceuticals Ltd. Follow us to see another collaboration to be announced soon. @InSilicoMeds https://t.co/Ty61zTl6Kj

[Insilico Medicine @InSilicoMeds]

Dear Friends, we have some exciting news! @InSilicoMeds just nominated a preclinical candidate (PCC) for kidney fibrosis, an age-related process implicated in multiple diseases. https://t.co/HHbJW9UtDS

[Alex Aliper @AlexAliper]

https://t.co/2xmLmEpmg5

[Syngenta @Syngenta]

We're always looking for new ways to accelerate innovation and help growers. Our partnership with @InSilicoMeds will unlock the transformative power of AI to make this happen.
#AI4AG #AgTech #SyngentaCropProtection

[Insilico Medicine @InSilicoMeds]

We @InSilicoMeds are extremely proud to announce that the first fully AI-designed #drug candidate is entering the clinic! Both the biological #target and the molecules were discovered using #AI. For more info please watch our video documentary: https://t.co/X418IBiZCj

[Syngenta @Syngenta]

Excited to announce our collaboration with @InSilicoMeds to use #artificialintelligence & deep learning to accelerate the invention of new, more sustainable products & technologies for growers:
https://t.co/qw5NyYuI8Z #AI4Ag #SyngentaCropProtection

[Alex Aliper @AlexAliper]

Very excited to announce our collaboration with Pfizer!

https://t.co/I2lNT1RNjZ

[Longevity Technology @LongevityTech]

@InSilicoMeds’ Dr Alex Zhavoronkov defines #Longevity
The “MMA fighter” of Longevity talks business models, AI drug discovery & working with the right investors.
https://t.co/TdjsxmYp0Z
@biogerontology #investment #AI #Juvenescence @sergeyyoung200 #Sinovation #MMA @gbpalantir

[Alex Zhavoronkov, PhD (aka Aleksandrs Zavoronkovs) @biogerontology]

Celebrities tweet, superstar editors brief. Deeply honored to have our paper on deep generative model with @A_Aspuru_Guzik mentioned in @NatRevDrugDisc 🙏👩‍💻
https://t.co/lyDilx5wy4